Join ACC's Prevention of Cardiovascular Disease Member Section this Wednesday, April 9 at 1 p.m. ET for a recap of ACC.25 prevention content and its influence on clinical practice. The webinar will ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during ...

The FRESH-UP study demonstrated that for patients with chronic heart failure (HF), liberal fluid intake did not result in a significant difference in health status vs. fluid restriction up to 1500 mL ...

Use of a cerebral embolic protection (CEP) device did not decrease the incidence of stroke within 72 hours after participants underwent TAVI, according to new research presented during a Late-Breaking ...

In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they underwent open-heart bypass surgery (CABG) or a less invasive procedure called ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

The Advance-HTN trial showed that lorundrostat effectively lowered 24-hour SBP at 12 weeks among patients with uncontrolled and treatment-resistant hypertension vs. placebo. Participants at 103 U.S.